Understanding Factors Affecting University A Students' Decision to Receive an Unlicensed Serogroup B Meningococcal Vaccine.
During March-November 2013, five cases of serogroup B meningococcal disease occurred among University A undergraduates. The Centers for Disease Control and Prevention used the unlicensed MenB-4C (Bexsero, Novartis Vaccines), a serogroup B meningococcal vaccine, to control the outbreak. All undergraduates (n = 19,257) were offered two doses; 51% of undergraduates received ≥1 dose of MenB-4C. We conducted a knowledge, attitudes, and practice survey to understand which factors and sources of information impacted their decision on whether or not to receive vaccine. An anonymous online survey was sent to University A undergraduates. The survey was implemented in June 2-30, 2014, and covered demographics, MenB-4C vaccination decision, and sources of information. Descriptive analyses were conducted. A total of 1,341 students completed the survey (response rate = 7.0%), of these 873 received ≥1 dose of MenB-4C. Among vaccinated respondents, the predominant reasons for receiving vaccine were knowledge of disease severity, parental recommendation, and believing that vaccination offered the best protection. Among unvaccinated respondents, the predominant reasons for not receiving vaccine were perception of low disease risk and concern over vaccine newness and safety. Respondents' top primary sources of information were e-mails from the university followed by their parents. Reasons behind respondents' decision to receive an unlicensed vaccine were similar to those reported for routinely recommended vaccines. Given the challenges around communicating the importance of receiving a vaccine that is not routinely recommended, respondents' primary sources of information, the university and their parents, could be targeted to improve coverage rates.